Through antisense-induced single-, double-, and multiexon skipping, we have previously demonstrated restoration of dystrophin expression in Duchenne muscular dystrophy (DMD) patientderived muscle cells in vitro. In this study we further explored the frontiers of this strategy by using specific combinations of 2V-O-methyl phosphorothioate antisense oligonucleotides (AONs) targeting either one or multiple exons. We show that skipping efficiencies may indeed be improved by targeting two putative splicing regulatory sequences within one exon. In particular, such double targeting was effective for the thus far bunskippableQ exons 47 and 57. We previously reported the feasibility of multiexon skipping spanning exon 45 to exon 51, using a combination of AONs targeting both outer exons (45 and 51). This would be applicable to 13% of all DMD patients. We here explored the frontiers of multiexon skipping both to increase the number of patients that can be treated with the same set of AONs and to mimic large deletions found in relatively mildly affected BMD patients. We aimed at inducing larger multiexon-skipping stretches, such as exons 17-51, exons 42-55, and exons 45-59. However, this appeared complicated and may be dependent on cotranscriptional splicing and the size of the flanking introns.
INTRODUCTION
In contrast to the very severe Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) is a mild to moderately severe neuromuscular disease [1] . Both DMD and BMD patients carry deletions in the dystrophin gene [2] [3] [4] . This protein provides a mechanical link between the cytoskeleton and the muscle membrane and has a function in maintaining muscle fiber stability [5] . The majority of Becker patients carry deletions within the central domain that do not disrupt the reading frame of the gene and thus allow the synthesis of internally deleted dystrophins that retain (part of) their functionality [2] . In contrast, mutations that do disrupt the open reading frame and thus give rise to prematurely truncated proteins are nonfunctional and associated with the severe Duchenne muscular dystrophy [3, 6] .
A clinically applicable therapy for DMD is currently not available. One of the most promising strategies aims to convert an out-of-frame into an in-frame mutation [7, 8] . This can be achieved by antisense oligonucleotides (AONs) that interfere with splice sites or regulatory elements within the exon and thus induce the skipping of specific exons on pre-mRNA level. In this way the reading frame can be restored, enabling the synthesis of an internally deleted, Becker-like dystrophin. We have previously reported single exon skipping and restored dystrophin synthesis upon AON treatment of muscle cell cultures derived from eight different DMD patients carrying different deletions and point mutations [9, 10] . Furthermore, the simultaneous, therapeutic skipping of two exons (socalled double-exon skipping) was induced after treating two patient-derived muscle cell cultures with a combination of AONs targeting two different exons [11] . Finally, we demonstrated the simultaneous skipping of exons 45 through 51 (multiexon skipping) by using a combination of AONs targeting the outer exons [11] . The in vivo applicability of this strategy has also been shown in the mdx mouse, which has a nonsense mutation in the inframe exon 23 [7, 12] . Intramuscular injections of AONs targeting the splice site of this exon in combination with F127 (a pluronic block copolymer) restored dystrophin synthesis in mdx mouse muscle to over 20% of wild-type levels and muscle function was improved [7] . Levels of up to 5% could be found in various muscle groups after systemic injection of the same AON [13] . After intramuscular injection of AONs in combination with a cationic polymer (polyethylenimine), intact AONs could be detected in muscle for at least 3 weeks by MALDITOF spectrometry [12] , and resulting skip-transcripts were detected for at least 4 weeks in wild-type mice. This indicates that in future clinical applications daily administration may not be required. Currently, different international clinical studies are being planned and initiated, in which AONs will be injected locally in muscles of DMD patients to obtain proof of feasibility and safety.
In the current study we further explored the frontiers of therapeutic exon skipping by using a combination of AONs, targeting either one or multiple exons. We have to date identified a series of 114 exon-internal AONs to induce the skipping of 35 exons in cultured muscle cells [14] . Our data suggest that effective exon-internal AONs are likely to act by steric hindrance of SR protein binding to exonic splicing enhancer (ESE) sites [15] . SR proteins [16] bind to exonic sequence motifs and recruit other splicing factors to mediate splicing [19] . For most exons that we studied, AON targeting of a single ESE was sufficient to induce significant levels of exon skipping [14] . However, for some exons the skipping efficiencies Using combinations of these AONs, however, exon 47 and 57 skipping was reproducibly induced at significant levels. For exon 57 combinations containing h57AON3 were most efficient, while for exon 47 all nonoverlapping combinations induced comparable levels of exon 47 skipping. In some cases an additional band could be observed in the exon 47 PCR, which was slightly shorter than the wild-type product. This band was not reproducible, was observed both in treated and in nontreated samples, and appeared to be a nonspecific PCR product containing DMD exons 72-74. (D) For exon 45 only one of the available AONs reproducibly induced skipping, albeit at low levels (h45AON5). Very low levels of exon skipping were occasionally observed for h45AON1 and h45AON4, but these were not reproducible. Exon 45 skipping could be achieved at much higher levels using combinations of AONs. The highest levels of exon 45 skipping were observed for combinations of h45AON5 and h45AON1 or h45AON3 and for h45AON1 and h45AON9. In contrast, a mixture of the overlapping h45AON2 and h45AON9 was ineffective. (E) For exon 2 only overlapping AONs were available. When the effective h2AON1 was combined with the ineffective, overlapping h2AON2, no skipping could be induced. This effect was not seen when h2AON1 was combined with the ineffective, less overlapping h2AON3. NT, not transfected; ÀRT, negative control; M, 100 bp size marker.
were low to zero. We thus hypothesized that skipping levels might be improved by the targeting of multiple ESE sites within one exon. Various combinations of AONs were tested for exons that could not yet be skipped, for exons that could be skipped only at low efficiencies, and for one exon that could already be skipped efficiently.
As mentioned, combinations of AONs can also be applied to induce multiexon skipping, i.e., the simultaneous skipping of an entire stretch of exons by targeting the two outermost exons [11] . The advantage of multiexon skipping is that the mutation specificity of the exon-skipping strategy is reduced. With single-and double-exon skipping, different mutations require the skipping of different exons, whereas multiexon skipping would be applicable for a larger group of mutations. For instance, the previously described exon 45-51 multiexon skipping would be beneficial for over 13% of all DMD patients reported in the Leiden DMD mutation database [17] . Theoretically, multiexon skipping also allows the engineering of large in-frame mutations known to be associated with milder Becker phenotypes. For instance, an exon 17-48 deletion has been described for a Becker patient who was still ambulant at 61, whereas in a 12-year-old boy with an exon 17-51 deletion the only symptoms were elevated CK levels and mild muscle pain after strenuous exercise [18, 19] . The residual dystrophin proteins in these patients are thus apparently largely functional. Multiexon skipping of exons 17-48 and exons 17-51 would be applicable to 25 and 40% of all DMD patients, respectively. A deletion of exons 48-59 (applicable to 15% of DMD patients) has been reported for a typical BMD patient [20] . We here tested the feasibility of inducing these larger multiexon skips. In addition, the feasibility of inducing exon 42-55 multiexon skipping was tested. This deletion has to our knowledge never been reported, but would be applicable to nearly 50% of DMD patients.
RESULTS AND DISCUSSION

Double Targeting within One Exon
We hypothesized that by targeting multiple ESEs within one exon, skipping efficiencies might be increased for exons that could not be skipped at high levels using individual AONs. The location of the AONs relative to putative ESEs (as predicted by ESEfinder) is depicted for each of these exons in Fig. 1A .
We first tested double targeting for two unskippable exons (exons 47 and 57). When we treated human control myotube cultures with different combinations of these AONs, significant levels of exon 47 and 57 skipping could be achieved as determined with RT-PCR analysis (Figs. 1B and 1C; Supplementary Table 1) . Interestingly, for exon 47 only combinations of nonoverlapping AONs induced exon skipping, while those that do overlap were ineffective (Supplementary Table 1) . Similarly, for exon 57 the combination of AONs that nearly overlap (h57AON1 and 2) did not induce exon skipping. This fits with our hypothesis that two mutually exclusive ESE sites are present in these exons.
For both exon 2 and exon 45 only a single AON reproducibly induced low levels of exon skipping (h2AON1 and h45AON5, respectively). Considerably higher levels of exon 45 skipping could be induced by combining the effective h45AON5 with ineffective AONs, as well as by combining two individually ineffective AONs (e.g., h45AON3 and h45AON9) (Fig. 1D) . (Fig. 1E) . This interference was not observed for a combination of h2AON1 with h2AON3 (which overlaps less than h2AON2). For exons 43 and 48, effective AONs induced only moderate levels of skipping. For these exons the skipping levels could not be increased by using combinations of AONs (Supplementary Table 1 ). In these exons three or even more ESEs may be present. Therefore, we targeted exon 48 with a combination of three different AONs, which still did not improve skipping levels. Thus, it seems more likely that the splicing of this exon is largely independent of ESE sites. This is supported by the fact that the splice sites predicted are perfect (3V splice site) or near perfect (5V splice site) and that only a few ESEs are predicted for exon 48.
Finally, we used combinations of exon 46-specific AONs, some of which were already very efficient individually. We aimed to increase skipping levels to (near) 100%. However, none of the combinations used further improved skipping levels compared to single targeting (Supplementary Table 1 ). This indicates that blocking one ESE site is sufficient to perturb the correct splicing of this exon. It is possible that the ESE sites of this exon are dependent on each other, so that by blocking one, more or all ESEs are inactivated. Alternatively, the secondary structure of the pre-mRNA may be changed upon AON binding so that the other ESE sites are no longer available for SR protein binding.
Interestingly, once more (partly) overlapping combinations appeared to interfere negatively with the individual exon-skipping capacities, irrespective of whether the single AONs were effective or ineffective. It was expected that combinations of two ineffective, overlapping AONs would also be ineffective, since they either both target no functional ESE site or both target the same two (or more) mutually exclusive ESE sites. For combinations of overlapping, effective AONs this finding was unexpected. It is possible, however, that these AONs compete with each other and force one another to detach from the target transcript in a dynamic process, thereby making the target site available again for SR proteins. Upon binding SR proteins will recruit other splicing factors to the splice sites and thus enhance exon inclusion rather than exon skipping. Table 2 ). To increase the chance that both AONs hybridize to the same pre-mRNA (which may increase the levels of multiexon skipping), we also designed several AONs consisting of two AONs linked to each other with 0 or 10 uracil nucleotides (U-linked AONs).
Unfortunately, we never observed multiexon skipping of exons 17-48 (tested 45 times, with different AON combinations and concentrations), exons 17-51 (tested 29 times), or exons 48-59 (tested 21 times), irrespective of whether we used patient or control myotube cultures or whether we transfected a combination of AONs or a Ulinked AON (data not shown).
The only combination with some potential was that of AONs targeting exons 42 and 55. We observed exon 42-55 skipping three times in 68 experiments (4%). As anticipated, the frequency was increased when the AONs were linked to one another (9 of 89 experiments (10%)) (Fig. 2) . We then tested this multiexon skipping in myotube cultures from patients with a deletion of exon 45 or exons 46-50.
Surprisingly we never observed exon 42-55 skipping (data not shown). As fewer exons have to be skipped and the resulting in-frame skip transcript should be more stable, since it is not subject to nonsense-mediated mRNA decay, this was unexpected. A possible explanation is that, as a consequence of the deletion, the sequence and timing of DMD splicing may be different in these patients compared to those in control cells.
Notably, we did occasionally observe in-frame exon 45-55 skipping, both in control and in patient myotube cultures (26%) (Fig. 2) . This was also seen in nontreated patient and control cultures at a similar frequency (~30%), indicating that this may originate from alternative splicing events.
Given that we have previously confirmed the feasibility of skipping exons 45-51, that we often observe spontaneous exon 45-55 skipping, and the fact that intron 44 is over 240 kb long, we deemed that inducing a multiexon skip starting at exon 45 might be more easily achieved. Therefore, we aimed at inducing the skipping of exons 45-59, which would still be beneficial for 30% of all DMD patients reported in our database. Treating control myotubes with AONs targeting exons 45 and 59 resulted in the intended exon 45-59 skipping only once in 17 experiments (6%) (Fig. 3, Supplementary Table 2 ). We also tested these AONs in duplicate in exon 51-55
RT-PCR analysis of dystrophin mRNA transcripts from control myotube cultures treated with a U-linked AON targeting exon 42 and exon 55 (h42AON1U10h55AON1). The experiment was performed five times with identical AON concentrations. At the top primers flanking the intended exon 42-55 multiexon skip were used, resulting in a wild-type band of~2.5 kb. Exon 42-55 skipping was observed once (fifth lane), while exon 45-55 skipping was seen in lane 4 and in the nontreated cells (NT). In addition, very faint bands of varying lengths can be observed in both treated and nontreated myotubes. Due to the low amount it was impossible to identify the nature of these fragments with sequencing analysis. At the middle and bottom primers flanking exon 42 and exon 55, respectively, were used to confirm successful transfection. Exon 42 and 55 skipping could be confirmed for each of the treated samples. Low levels of exon 42 skipping were also detected in nontreated cells. M, 100 bp size marker; ÀRT, negative control. deleted myotubes and observed exon 45-59 skipping once (Fig. 3) . We again detected a spontaneous exon 45-55 skipping product for control myotubes (18%) (data not shown). In addition, we now also observed a second intermediate product consisting of in-frame exon 45-60 skipping in 59% of treated human control myotubes and in both treated and nontreated patient myotube cultures (Fig. 3) . However, these levels were too low to result in detectable levels of dystrophin in patient myotubes as assessed by Western blotting (data not shown).
These results imply that multiexon skipping is more complicated and less reproducible than initially suggested and that it may not to be straightforwardly applicable. The fact that DMD pre-mRNA is cotranscriptionally spliced [21] means that for some of the intended multiexon skip combinations the upstream target exon (e.g., exon 17 in the exon 17-48/51 skip) is already joined to the preceding exon (exon 16) in the majority of the transcripts, when the downstream exon (exon 48/51) has yet to be transcribed. We further take into account that splicing does not occur consecutively. We observed intermediate products of exon 45-55 and exon 45-60 skipping more often than the intended exon 42-55 and 45-59 skipping. These intermediate products are both flanked by extremely long introns (intron 44 is 240 kb, intron 55 is 120 kb, and intron 60 is 96 kb). Therefore, the splicing of downstream shorter introns may well occur prior to the splicing of large introns, thus generating intermediate bexon blocksQ consisting of, e.g., exons 45-55 or exons 45-60. This fits with our observation of exon 45-55 skipping in over one-third of various nontreated control myotube samples. In an exon 45-55 exon block, the 3Vsplice site of exon 45 (predicted value 0.76) has to compete with that of exon 56 (predicted value 0.94). As the splice site of exon 56 is stronger and the exon block is located in an intronic sea of 360 kb, it is not inconceivable that the splicing machinery occasionally aberrantly omits the exon block. Consistent with this idea, we never observed exon 45-55 skipping in nontreated myotube cultures from the patient with an exon 51-55 deletion (this study, [9] ), in which intron 55 is largely deleted and may thus be more easily spliced out and, accordingly, exon 45-55 exon blocks are less likely to occur. For this patient we did observe exon 45-60 skipping in nontreated myotubes. Once again, these exons are flanked by what are, for this patient, the largest introns in this region.
In summary, we have shown that a combination of AONs targeting a single exon may increase exon skipping levels. This seems to apply especially for exons that were thus far difficult to skip. Multiexon skipping, on the other hand, seems to be more complex and dependent on cotranscriptional splicing, as well as the order of intron removal. Currently, the level and reproducibility of multiexon skipping are too low to allow the synthesis of sufficient levels of dystrophin, and therefore the therapeutic effect is expected to be limited. Thus, more information on the splicing process, in particular the sequence of intron removal in patient and control pre-mRNA transcripts and the presence of functional ESE sites, will be necessary to optimize this multiexon skipping strategy and allow future clinical applications.
MATERIALS AND METHODS
AONs and primers. All AONs used for the double-targeting and multiexon-skipping experiments were previously described (see Supplementary  Table 1 and 2) [11, 14, 15] . For the multiexon-skipping experiments we also tested linked AONs consisting of two AONs linked with or without 10 U nucleotides. All AONs contain 2-O-methyl RNA, phosphorothioate backbones, and 5V fluorescein labels and were manufactured by Eurogentec (Belgium). (RT-) PCR primers were chosen in exons flanking the skipped exons (Eurogentec; sequences available upon request).
FIG. 3.
RT-PCR analysis of dystrophin mRNA transcripts from control and patient myotube cultures treated with AONs targeting exon 45 and exon 59. An example of exon 45-59 skipping is shown for treated (+) control and patient (deletion exons 51-55) myotubes (third and fifth lane, respectively). Exon 45-60 skipping was observed in treated control myotubes (second lane) and in both treated and nontreated (NT) patient-derived myotubes. The wild-type band from the control myotube cultures (nearly 3 kb) is not visible, but a faint wild-type band of~2 kb can be seen for myotube cultures from the exon 51-55 deleted patient. M, 100 bp size marker; ÀRT, negative control.
Tissue culturing, transfection, and RT-PCR analysis. Control and DMD patient-derived myotube cultures were obtained as described previously [9, 22] . For the single exon-skipping experiments, transfections were performed at least twice with 200 nM each AON, whereas for the multiexon skipping transfections were performed with varying concentrations of AONs (100-500 nM). In all experiments polyethylenimine (PEI; ExGen 500; MBI Fermentas) was used according to the manufacturer's instructions, with 2 to 3.5 Al PEI per microgram of AON. Depending on the number of effective AONs available for each of the targeted exons, different combinations of AONs were tested (Supplementary Table 1 and 2). Separate solutions of AON-PEI complexes were prepared for each AON. Transfection efficiencies were generally over 80% based on the presence of nuclear fluorescent signals. RNA was isolated 24-48 h after transfection and RT-PCR analysis was performed as described previously [14] . Successful transfection of each AON was confirmed by RT-PCR analysis with primers in the exons flanking the targeted exons (i.e., flanking exon 17 and exon 48 for exon 17-48 multiexon skipping). PCR fragments were isolated from the agarose gel and sequencing analysis was performed as described previously [10] .
